Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era - Université de Lorraine Access content directly
Journal Articles Advances in Therapy Year : 2022

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Abstract

No abstract available

Dates and versions

hal-04168336 , version 1 (21-07-2023)

Identifiers

Cite

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin‐biroulet, et al.. Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy, 2022, 39 (5), pp.2281. ⟨10.1007/s12325-022-02082-9⟩. ⟨hal-04168336⟩
12 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More